Plus Therapeutics Announces New \$17.35 Million At-The-Market Equity Offering Program
AUSTIN, TX, June 5, 2026 – Plus Therapeutics, Inc. (NASDAQ: PSTV), a clinical-stage pharmaceutical company, has entered into a significant new equity distribution agreement with Canaccord Genuity LLC, potentially raising up to \$17,350,000 through the sale of its common stock in an at-the-market (ATM) offering. The agreement was formalized on June 1, 2026, and disclosed in a Form 8-K filed with the U.S. Securities and Exchange Commission (SEC).
Key Highlights for Investors
- Equity Distribution Agreement Details: Plus Therapeutics can, from time to time, sell shares of its common stock with an aggregate offering price of up to \$17.35 million. The sales will be made through Canaccord Genuity LLC, acting as the Company’s sales agent. The ATM structure allows the company to access capital efficiently in response to market demand.
- Sales Methods: Shares may be sold directly on the Nasdaq Capital Market or through other methods permitted by law, including negotiated transactions or block trades, as defined in Rule 415(a)(4) of the Securities Act of 1933.
- Commission and Fees: Canaccord Genuity will earn a commission of 3.0% of the gross proceeds from the sales. Plus Therapeutics will also reimburse Canaccord for up to \$75,000 in reasonable out-of-pocket expenses, including legal fees. Customary indemnification rights in favor of the Agent are included.
- Termination Flexibility: The company is under no obligation to sell any shares and can suspend or terminate the offering at any time. The agreement terminates upon the sale of all authorized shares or by either party at any time without liability.
- Use of Proceeds: Net proceeds from the offering will be used for general corporate purposes and working capital. This flexible use of funds may include R&D, clinical trials, or operational expansion, but the company has not specified particular projects at this time.
- Regulatory Compliance: The shares will be offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-296411), filed with the SEC on June 2, 2026, and a related prospectus supplement covering this ATM program. Sales are subject to the limitations of General Instruction I.B.6. of Form S-3, which governs the aggregate market value of shares eligible for sale.
- Shareholder Protections: The company retains the ability to set minimum prices for the sale of its shares and may direct the agent not to sell if pricing is unfavorable.
Why This Matters to Shareholders & Potential Market Impact
- Potential Dilution: If the full \$17.35 million is raised through share issuance, existing shareholders may experience dilution of their ownership percentage.
- Flexible Funding for Growth: The ATM program provides Plus Therapeutics with a flexible and efficient mechanism to raise capital as needed, bolstering its financial position and supporting ongoing operations and development programs. This could be positive for the company’s clinical and commercial progress.
- Market Price Sensitivity: The announcement and execution of an ATM can impact the share price, depending on investor perceptions of the company’s funding needs and the potential for dilution. Large or sustained ATM sales can sometimes exert downward pressure on the stock price, especially if the market views it as a sign the company needs capital to sustain operations.
- No Immediate Obligation to Sell Shares: The company is not required to sell any shares under this agreement, which offers flexibility and may mitigate concerns about immediate dilution.
Additional Details
- Company Information: Plus Therapeutics, Inc. is headquartered in Austin, Texas, and its shares trade on the Nasdaq Capital Market under the symbol PSTV. The company was previously known as Cytori Therapeutics, Inc. and MacroPore Inc.
- Filing Officer: The Form 8-K was signed by Andrew Sims, Chief Financial Officer.
Key Takeaways
- This ATM equity program is a potentially price-sensitive development for Plus Therapeutics shareholders, as it provides the company with financial flexibility, but also may introduce dilution risk.
- Investors should monitor the pace and amount of share sales under the ATM for signs of company funding needs and potential impact on share value.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Investors should consult their financial advisors and review official filings, including the Form 8-K and accompanying prospectus supplement, before making any investment decisions. Plus Therapeutics’ actual use of proceeds and the impact of the ATM program may differ from current expectations due to a variety of risks and uncertainties.
